Xtandi

Drug - Xtandi (enzalutamide) [Astellas Pharma US, Inc.]  

September 2014

Therapeutic area - Oral Oncology

Approval criteria

Diagnosis of metastatic castration-resistant prostate cancer

Quantity limits

• The initial PA will allow a first fill of 14 days [fifty-six, 40 mg tablets] with one refill to ensure patient tolerance with therapy before approving in larger, monthly quantities
• Monthly quantity limit = 136

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411